Ashvattha Therapeutics Presents Preclinical Data on anti-VEGF Nanomedicine D-4517.2 at the 2023 ARVO…
<!-- Name:DistributionId Value:8825608 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4573 -->…
Browsing Tag
ARVO
1-Year Outcomes of Phase 3 Study for SB15, Proposed biosimilar to Eylea (aflibercept), Presented at…
<!-- Name:DistributionId Value:8823565 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value: -->…
Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the…
<!-- Name:DistributionId Value:8823475 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4573 -->…
Doheny Eye Institute Announces Upcoming Presentations at ARVO 2023 Annual Meeting
<!-- Name:DistributionId Value:8812683 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value: -->…
Clearside Biomedical’s Suprachoroidal Injection Platform to be Featured at The Association for…
<!-- Name:DistributionId Value:8810871 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4573 -->…
Atsena Therapeutics Announces Six-Month Data from Phase I/II Clinical Trial of ATSN-101 to be…
<!-- Name:DistributionId Value:8805147 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4570 -->…
DIAGNOS and ETS to Present Ground-breaking Research on Mass Screening for Macular Edema at ARVO 2023
<!-- Name:DistributionId Value:8749103 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:9500 -->…
DIAGNOS et l’ÉTS présenteront une recherche novatrice sur le dépistage de masse de…
<!-- Name:DistributionId Value:8749103 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:9500 -->…
Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome…
-- Data Demonstrate Rapid and Complete Wound Healing, with Six of Eight (75%) Patients Achieving Complete Healing within Four Weeks; All Remained Healed Through End of Follow-Up ---- All Patients with Pain at Baseline Reported Zero Pain by…
Graybug to Present Preclinical Data for GB-401 in Primary Open-Angle Glaucoma at the 2022 ARVO…
BALTIMORE, April 27, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced a poster…